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Abstract Lower serumvitaminB12 levels have been related
to adverse metabolic health profiles, including adiposity. We
used a Mendelian randomization design to test whether this
relation might be causal. We included two Danish popula-
tion-based studies (ntotal = 9311). Linear regression was
used to test for associations between (1) serum vitamin B12
levels and body mass index (BMI), (2) genetic variants and
serum vitamin B12 levels, and (3) genetic variants and BMI.
The effect of a genetically determined decrease in serum
vitamin B12 on BMI was estimated by instrumental variable
regression. Decreased serum vitamin B12 associated with
increased BMI (P\ 1 9 10-4). A genetic risk score based
on eight vitamin B12 associated variants associated strongly
with serum vitamin B12 (P\ 2 9 10-43), but not with BMI
(P = 0.91). Instrumental variable regression showed that a
20% decrease in serum vitamin B12 was associated with a
0.09 kg/m2 (95% CI 0.05; 0.13) increase in BMI
(P = 3 9 10-5), whereas a genetically induced 20%
decrease in serum vitamin B12 had no effect on BMI [-0.03
(95% CI -0.22; 0.16) kg/m2] (P = 0.74). Nevertheless, the
strongest serum vitamin B12 variant, FUT2 rs602662, which
was excluded from the B12 genetic risk score due to potential
pleiotropic effects, showed a per allele effect of 0.15 kg/m2
(95%CI0.01; 0.32) onBMI (P = 0.03). This associationwas
accentuated including two German cohorts (ntotal = 5050),
with a combined effect of 0.19 kg/m2 (95% CI 0.08; 0.30)
(P = 4 9 10-4). We found no support for a causal role of
decreased serum vitaminB12 levels in obesity. However, our
study suggests that FUT2, through its regulation of the cross-
talk between gutmicrobes and the human host, might explain
a part of the observational association between serumvitamin
B12 and BMI.
Keywords BMI  Cobalamin  FUT2  Mendelian
randomization  Secretor/nonsecretor  Vitamin B12
Introduction
Human obesity is a highly heterogeneous disorder where
multiple factors, especially related to lifestyle, contribute to
the pathogenic development. A high degree of heritability
has also been established [1], and a substantial number of
genetic variants associated with obesity-related phenotypes
have been identified [2, 3]. The pathways and mechanisms
underlying these genetic associations have not been fully
elucidated, but central nervous system and adipose tissue
biology have been highlighted. Nevertheless, the genetic
variants only explain a small fraction of the phenotypic
Electronic supplementary material The online version of this
article (doi:10.1007/s10654-016-0215-x) contains supplementary
material, which is available to authorized users.
& Kristine H. Allin
kristine.allin@sund.ku.dk
1 The Novo Nordisk Foundation Center for Basic Metabolic
Research, Section of Metabolic Genetics, Faculty of Health
and Medical Sciences, University of Copenhagen,
Universitetsparken 1, 2100 Copenhagen, Denmark
2 Institute of Clinical Chemistry and Laboratory Medicine,
University Medicine Greifswald, Greifswald, Germany
3 Research Centre for Prevention and Health, The Capital
Region of Denmark, Copenhagen, Denmark
4 Department of Clinical Experimental Research,
Rigshospitalet, Glostrup, Denmark
5 Faculty of Health Sciences, University of Southern Denmark,
Odense, Denmark
6 Faculty of Health Sciences, University of Aarhus, Aarhus,
Denmark
123
Eur J Epidemiol (2017) 32:125–134
DOI 10.1007/s10654-016-0215-x
variance [2, 3], indicating that yet undiscovered mecha-
nisms could be essential in the obesity pathogenesis.
Vitamin B12 (cobalamin) is solely produced by Bacteria
and Archaea [4] and the only natural source of this vitamin
for humans are foods of animal origin such as meat, fish,
eggs, and dairy products. In humans, vitamin B12 functions
as an essential coenzyme in various cellular functions such
as cellular energy metabolism, DNA synthesis and methy-
lation, as well as protein, lipid, and carbohydrate synthesis
[5]. Several studies have observed associations between
lower circulating vitamin B12 levels and adverse metabolic
health profiles, with insulin resistance, cardiovascular dis-
orders, and adiposity as important features [6–10].
The heritability of serum vitamin B12 levels has in a
study of mono- and dizygotic twins been estimated to be
59% [11]. Several studies have, in genome-wide associa-
tion studies (GWAS) and using sequencing efforts, iden-
tified at least 12 genetic variants robustly associated with
circulating vitamin B12 levels [12–16]. Interestingly,
despite using hypothesis-free genome-wide approaches, the
vast majority of the identified single nucleotide polymor-
phisms (SNP) are situated in or near genes encoding pro-
teins responsible for the absorption, processing, and
coenzymatic activity of vitamin B12 [16].
These genetic variants allow the construction of a
genetic risk score (GRS) that can serve as a relatively
unbiased instrument for serum vitamin B12 levels in a
Mendelian randomization study [17]. Here, we used this
instrument in two Danish population-based cohorts con-
ducted at a time point where legislation did not allow
fortification with vitamin B12 (or folate) of food items
[18], to test the hypothesis that lower serum vitamin B12
levels are causally related to obesity.
Materials and methods
Study populations
The Danish population-based Inter99 study (ClinicalTri-
als.gov ID-no: NCT00289237) is a non-pharmacological
intervention study for ischemic heart disease, initiated in
1999 at the Research Centre for Prevention and Health,
Glostrup, Denmark. A random sample of 13,016 individ-
uals living in Copenhagen County from seven different age
groups (30–60 years, grouped with 5 year intervals) was
drawn from the Civil Registration System and 6784 of
these attended the health examination [19].
The Danish Health2006 cohort is a population-based study
of general health and chronic diseases such as type 2 diabetes
and cardiovascular disease in individuals aged 18–69 years.
The study was initiated in 2006 at Research Centre for
Prevention and Health, Glostrup, Denmark, and participants
were drawn as a random sample of the background population
living in the south-western part of the greater Copenhagen
area. A total of 7770 were invited to participate and 3471
entered and participated in the health examination [20].
The Study of Health in Pomerania (SHIP-0) is a popu-
lation-based study in West Pomerania, a rural region in
north-east Germany [21], where 6265 individuals, aged
20–79 years, were invited, of which 4308 participated.
Data collection was performed between 1997 and 2001.
For SHIP-TREND, an independent random sample of 8826
individuals aged 20–79 years was drawn from the same
region between 2008 and 2012, and 4420 participated.
All participants gave written informed consent. The
studies were approved by local ethics committees and
conformed to the principles of the declaration of Helsinki.
Anthropometric, biochemical, and lifestyle measures
In all cohorts, body weight (kg), waist circumference (cm),
hip circumference (cm) and height (cm) were measured in
light indoor clothes and without shoes. Body mass index
(BMI) was calculated as body weight divided by the
squared height in meters (kg/m2). In the Health2006 cohort
body fat percentage was measured using bioimpedance.
For the Danish cohorts, vitamin B12 was measured in
serum obtained from fasting blood samples, stored at
-20 C until the analyses were performed in 2008. For the
German cohorts, blood samples were analyzed immedi-
ately or stored at -80 until analysis. In all cohorts, serum
vitamin B12 was measured using a competitive chemilu-
minescent enzyme immunoassay (CENTAUR or Dimen-
sion Vista platform, Siemens Healthcare Diagnostics),
performed by Institute of Clinical Chemistry and Labora-
tory Medicine, University Medicine Greifswald, Germany.
In the Danish cohorts, all lifestyle factors were esti-
mated from self-reported questionnaire data. A three-point
dietary score was developed based on a 48-item food fre-
quency questionnaire and categorized as; (1) unhealthy, (2)
moderately healthy, and (3) healthy [22]. Alcohol intake
was estimated as the total units of alcohol (1 unit equals 12
grams of alcohol) per week. The level of physical activity
was estimated summing the time spent actively commuting
(min/week) and time spent on leisure time physical activity
(min/week). Subsequently, four categories were created;
(1) 0–2 h/week, (2) 2–4 h/week, (3) 4–7 h/week, and (4)
7–12 h/week [23]. Smoking habits were divided into three
classes: (1) never smoked, (2) former smoker, (3) daily and
occasional smoker [24].
Genotyping, SNP selection, and genetic risk score
Genotyping is described in detail in Supplemental Mate-
rials and Methods. Inter99 and Health2006 were genotyped
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using the Human Exome BeadChip on an Illumina HiScan
system (Illumina). In Inter99 a total of 6161 individuals
were genotyped and passed all quality control criteria and
the corresponding number was 2914 for Health2006. The
average call rate for all SNPs on the Human Exome
BeadChip was 99.0%.
The SNPs for the GRS were selected based on a joint
Icelandic and Danish sequencing initiative reporting 11 loci
associated genome-wide significantly (P\ 5 9 10-8) with
serum vitamin B12 levels [16], of which six were validation
of previous GWAS in European and Chinese populations
[12–15]. Of the 11 serum vitamin B12 associated SNPs [16],
ten (MMAA rs2270655,MUT rs1141321, CUBN rs1801222,
TCN1 rs34324219, CLYBL rs41281112, ABCD4 rs3742801,
CD320 rs2336573, TCN2 rs1131603, FUT6 rs778805 and
FUT2 rs602662) could be retrieved from the Human Exome
BeadChip, whereas one (MMACHC rs12272669) was not
represented. The SNP quality of the ten SNPs retrieved from
the Human Exome BeadChip was estimated based on
genotype call rate ([95%), Hardy–Weinberg equilibrium
(HWE) (P[ 0.005), or cross-hybridization with the
X-chromosome, and all ten SNPs passed these filters (HWE;
P[ 0.04, call rate[98.1%).
The genotypes were coded according to number of
serum vitamin B12 decreasing alleles. For four SNPs the
minor allele, and for six SNPs the major allele, were
considered the effect allele which had frequencies ranging
from 3.0 to 96.9% in Inter99 and from 3.0 to 97.2% in
Health2006. A full vitamin B12 GRS (full-B12 GRS) was
calculated by summarizing the number of serum vitamin
B12 decreasing alleles for the ten SNPs for each individual.
Additionally, a B12 GRS without FUT2 rs602662 and
FUT6 rs778805 (B12 GRS) was constructed to circumvent
the pleiotropic effects of FUT2 and FUT6.
SHIP-0 was genotyped using the Affymetrix Genome-
Wide Human SNP Array 6.0. FUT2 rs602662 was imputed
based on the 1000G project (phase 1, European super-
population, March 2012 release [25]) with an imputation
quality score of 0.99. Genotype data were available for
4064 subjects. Only a subset of SHIP-TREND (n = 986)
was genotyped. This was done using the Illumina Human
Omni 2.5 array, and rs602662 was directly genotyped with
a callrate of 99.8% obeying HWE (P = 0.02).
Statistical analyses
The statistical analyses were performed using the statistical
software R version 3.1.1 (http://www.r-project.org/) and
Stata (version 13.1; StataCorp). P values below 0.05 were
considered statistically significant. Linear regression
models (adjusted for age and sex) were used to test for
association between (1) serum vitamin B12 levels and
BMI, (2) SNPs or B12 GRS and serum vitamin B12 levels,
and (3) SNPs or B12 GRS and BMI. The serum vitamin
B12 and BMI association was additionally tested using
multifactor adjustment (diet, alcohol consumption, physi-
cal activity, and smoking). Association between the B12
GRS and potential confounders were tested using linear
regression models for continuous outcomes (age and
alcohol consumption) and logistic regression for categori-
cal outcomes (diet, physical activity, and smoking).
Associations between individual SNPs or the B12 GRS and
serum vitamin B12 levels/BMI were analyzed using an
additive model. The FUT2 rs602662 genotype was addi-
tionally analyzed using a dominant model. Explained
phenotypic variance (R2) was estimated using unadjusted
linear models. The effect of a genetically determined
decrease in serum vitamin B12 on BMI was estimated
using unadjusted instrumental variable regressions. These
were performed using the ivreg function of the ‘AER’
package in R and the ivregress command in Stata, both
using two-stage least-squares regression. The strengths of
the instruments were evaluated by F-statistics from first
stage regressions. In addition to using the B12 GRS as an
instrument, we also used each of the variants as separate
instruments, which is equivalent to using a GRS where
each variant is weighted based on its association with
serum vitamin B12 [26]. To test for directional pleiotropy
and to evaluate the robustness of our findings, we also
applied MR-Egger regression. Pleiotropy was evaluated by
the MR-Egger test which tests whether the intercept differs
from zero and by visually inspecting Funnel plots for
asymmetry [26]. The combined effect across study popu-
lations was estimated using fixed-effect model meta-anal-
yses performed by the rma function of the ‘metafor’
package in R. Linkage disequilibrium was estimated using
SNAP (http://www.broadinstitute.org/mpg/snap/) in data
from the European panel of HapMap phase 3 data.
Data on BMI from the Genetic Investigation of
Anthropometric Traits (GIANT) consortium was obtained
from the European ancestry dataset (http://www.broad
institute.org/collaboration/giant/index.php/GIANT_con
sortium_data_files).
Results
The phenotypic characteristics of the two Danish cohorts,
Inter99 and Health2006, are shown in Supplementary
Table 1. Individuals were middle-aged, with a median BMI
of 25.6 and 25.2 kg/m2, respectively. Serum vitamin B12
levels were higher in Health2006 compared to Inter99, but
similar among women and men within cohorts (Supple-
mental Table 1).
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Observational association between serum vitamin
B12 levels and BMI
Decreasing levels of serum vitamin B12 were associated
with increasing BMI in the two Danish cohorts (Fig. 1).
A BMI difference of 0.48 (95% CI 0.19; 0.76) kg/m2 and
0.64 (95% CI 0.26; 1.02) kg/m2 was observed when
comparing the first and third tertile of serum vitamin B12
levels in Inter99 and Health2006, respectively. Accord-
ingly, a 20% decrease in serum vitamin B12 levels was
associated with an increase in BMI of 0.10 (95% CI 0.05;
0.14) kg/m2 (P = 1 9 10-4) in Inter99 and 0.19 (95% CI
0.10; 0.27) kg/m2 (P = 3 9 10-5) in Health2006. Linear
regression model additionally adjusted for lifestyle factors
(diet, alcohol consumption, physical activity, and smok-
ing), as well as exclusion of type 2 diabetes patients
receiving anti-diabetic treatment (nInter99 = 71,
nHealth2006 = 66) showed similar results (Supplemental
Table 2).
In addition to BMI, decreasing levels of serum vitamin
B12 were associated with increasing waist circumference
and body fat percentage. A 20% decrease in serum vitamin
B12 levels was associated with an increase in waist cir-
cumference of 0.23 (95% CI 0.11; 0.35) cm
(P = 3 9 10-4) in Inter99 and 0.46 (95% CI 0.24; 0.69)
cm (P = 6 9 10-5) in Health2006. Body fat percentage
was only measured in Health2006, where a 20% decrease
in serum vitamin B12 levels was associated with an
increase in body fat percentage of 0.29 (95% CI 0.16;
0.42)% (P = 1 9 10-5). Decreasing levels of serum
vitamin B12 were also associated with increasing waist/hip
ratio in Health2006 (P = 0.03) but not in inter99
(P = 0.14).
Genotypes and serum vitamin B12 levels
The ten SNPs included in the full-B12 GRS each associ-
ated with decreased serum vitamin B12 levels in both
Inter99 and Health2006 (Supplemental Table 3). The SNP
showing the strongest association was FUT2 rs602662 with
a per G-allele decrease in serum vitamin B12 of -10 (95%
CI -11; -8)% (P = 3 9 10-37) according to an additive
model in Inter99. However, the median serum vitamin B12
levels suggested that a dominant model would be more
appropriate. Comparing homozygous/heterozygous G-al-
lele carriers with homozygous A-allele carriers showed a
serum vitamin B12 level decrease of -20 (95% CI -22;
-17)% (P = 1 9 10-51). A similar association pattern
was observed in Health2006 (Supplemental Table 3).
The full-B12 GRS associated strongly with serum vita-
min B12 levels, with a per effect allele decrease of -7
(95% CI -8; -7)% (P = 5 9 10-104) in Inter99, and a
similar association was observed in Health2006 (Supple-
mental Table 4). However, the overall aim of constructing
a GRS was to obtain an instrument for serum vitamin B12
levels not influenced by potential confounders. FUT2 and
FUT6 are known to determine ABH antigen secretor/non-
secretor status and be involved in the creation of Lewis
antigens, respectively. Hence, both could have pleiotropic
effects, and therefore, we also analyzed a GRS excluding
3rd tertile of 
vitamin B12
2nd tertile of 
vitamin B12
1st tertile of 
vitamin B12
xam-nimxam-nimxam-nim
532-111933-6323689-043
033-16924-1331403-034
Fig. 1 Observational
association between serum
vitamin B12 levels divided in
tertiles and BMI. Dots and
triangles indicate mean BMI
and error bars represent
standard errors. Black dots
represent Inter99 and grey
triangles represent Health2006.
P values are from age and sex
adjusted linear regression of
BMI on serum vitamin B12
levels
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FUT2 rs602662 and FUT6 778805 (B12 GRS). The B12
GRS was not associated with potential confounders
including age, sex, diet, alcohol consumption, physical
activity, and smoking (Table 1). The proportion of physi-
cally inactive individuals was seemingly different among
the B12 GRS allele groups, however, the direction of effect
was opposite in the two cohorts, which may suggest that
this is a chance finding (type 1 error). The B12 GRS
showed a per allele decrease in serum vitamin B12 of -7
(95% CI -8; -7)% (P = 2 9 10-72) in Inter99, and -6
(95% CI -7; -5)% (P = 2 9 10-43) in Health2006
(Fig. 2; Supplemental Table 4). The F-statistics for the
models were 331 in Inter99 and 197 in Health2006. The
B12 GRS explained 5.5 and 6.7% of the phenotypic vari-
ance in serum vitamin B12 in Inter99 and Health2006,
respectively (Supplemental Table 4).
B12 GRS and BMI
If decreased levels of serum vitamin B12 cause increased
BMI, the B12 GRS would, given its strong association with
serum vitamin B12 levels, expectedly also associate with
increased BMI. However, we observed no association
between the B12 GRS and BMI in either Inter99 or
Health2006. A fixed-effect model was used to combine the
effect sizes from the two cohorts and resulted in a per allele
effect of 0.00 (95% CI -0.07; 0.06) kg/m2 (P = 0.91)
(Table 2). Accordingly, when analyzed separately, none of
the eight SNPs included in the B12 GRS associated with
BMI in the two cohorts (data not shown).
Observational versus genetic associations
To directly compare the observational effect of decreased
serum vitamin B12 levels on BMI with the effect of
genetically induced low serum vitamin B12 levels on BMI,
we performed an instrumental variable analysis. The
combined observational effect of a 20% decrease in serum
vitamin B12 on BMI in the two cohorts was an increase of
0.09 (95% CI 0.05; 0.13) kg/m2, (P = 3 9 10-5), whereas
a genetically induced 20% decrease in serum vitamin B12
had no effect on BMI (-0.03 (95% CI -0.22; 0.16) kg/m2,
P = 0.74). Since we observed an association between
decreased serum vitamin B12 levels and BMI but no
association between genetically induced decreased serum
vitamin B12 levels and BMI, the present results do not
support a causal role of serum vitamin B12 levels on BMI.
However, as the observational estimate (0.09) is included
in the 95% CI of the genetic estimate (-0.22; 0.16), we
cannot completely rule out causality (Fig. 3).
FUT2 genotype and BMI
We hypothesized that FUT2 rs602662, through yet unde-
scribed pleiotropic effects, could explain a portion of the
observational effect between serum vitamin B12 and BMI
given the strong association with serum vitamin B12
Table 1 Association between the B12 GRS and potential confounders
Number of vitamin B12 decreasing alleles
Inter99 5 or less (n = 785) 6 (n = 1377) 7 (n = 1797) 8 (n = 1313) 9 or more (n = 809) Ptrend
Women, n (%) 420 (54) 678 (50) 928 (52) 647 (49) 431 (53) 0.39
Age, years 45 (40–50) 45 (40–50) 45 (40–50) 45 (40–55) 45 (40–50) 0.75
Unhealthy diet, n (%)a 117 (16) 195 (15) 278 (16) 210 (17) 126 (16) 0.52
Alcohol consumption, units per weekb 7 (3–14) 7 (2–14) 7 (2–14) 6 (2–14) 6 (3–14) 0.93
Physical inactivity, n (%)c 269 (36) 452 (35) 598 (36) 408 (33) 239 (32) 0.07
Current smokers, n (%)d 330 (43) 507 (37) 706 (40) 517 (40) 319 (40) 0.23
Health2006 5 or less (n = 370) 6 (n = 630) 7 (n = 842) 8 (n = 624) 9 or more (n = 391) Ptrend
Women, n (%) 200 (54) 342 (54) 446 (53) 348 (56) 224 (57) 0.49
Age, years 49 (41–60) 51 (40–61) 51 (41–60) 50 (41–60) 50 (40–60) 0.52
Unhealthy diet, n (%)a 24 (7) 44 (7) 53 (6) 43 (7) 23 (6) 0.89
Alcohol consumption, units per weekb 6 (2–13) 7 (2–14) 6 (2–13) 6 (2–12) 6 (2–14) 0.25
Physical inactivity, n (%)c 146 (40) 275 (45) 388 (46) 304 (49) 189 (49) 0.003
Current smokers, n (%)d 95 (26) 167 (27) 202 (24) 173 (28) 98 (25) 0.87
Values are median (IQR) unless otherwise specified. Ptrend are from linear regressions for continuous potential confounders (age and alcohol) and
from logistic regressions for categorical potential confounders: a Unhealthy diet vs. moderately healthy and healthy diet; b 1 unit = 12 g of
alcohol; c Physical activity\4 h per week versus C4 h per week; d Current smokers versus former and never smokers
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No. of 
individuals
Fig. 2 Association between the
B12 GRS and serum vitamin
B12 levels. Vitamin B12
decreasing alleles ranged from 2
to 13. Individuals with B5 or
C9 alleles were grouped to
obtain a reasonable number of
individuals in each group. Dots
and triangles indicate median
serum vitamin B12 and error
bars indicate interquartile
range. P values are from age
and sex adjusted linear
regression
Table 2 Association between the B12 GRS and BMI
n Weight (%) Per allele effect, kg/m2 (95% CI) P value
B12 GRS
Inter99 6076 68.5 -0.03 (-0.11;0.06)
Health2006 2854 31.5 0.04 (-0.08;0.17)
Fixed-effect model 0.00 (-0.07;0.06) 0.91
Heterogeneity: I2 = 0.0%, P = 0.35
Per allele effects are from linear regression analyses of the B12 GRS on BMI adjusted for age and sex
Observational (a 20% decrease in serum vitamin B12)
Cohort n Weight, % Effect, kg/m2 (95% CI)
Inter99 5969 67.5 0.08 (0.03;0.13)
Health2006 3336 32.5 0.14 (0.05;0.23)
)31.0;50.0(90.0ledomtceffe-dexiF
Heterogeneity, I2 =34.1 %, P=0.22
Genetic (a genetically induced 20% decrease in serum vitamin B12) 
Cohort n Weight, % Effect, kg/m2 (95% CI)
Inter99 5670 76.0 -0.09 (-0.30;0.13)
Health2006 2770 24.0 0.15 (-0.23;0.53)
)61.0;22.0-(30.0-ledomtceffe-dexiF
Heterogeneity,  I2=12.5 %, P=0.29
Fig. 3 Association between
serum vitamin B12 levels and
BMI. Squares indicate effect
estimates from Inter99 and
Health2006, sized according to
the weight of each study in the
meta-analyses. Diamonds
indicate effect estimates from
fixed-effects meta-analysis and
error bars indicate 95% CI
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(Supplemental Table 3). The serum vitamin B12 decreas-
ing FUT2 rs602662 G-allele associated with increased BMI
when combining Inter99 and Health2006 in a fixed-effects
meta-analysis (0.15 (95% CI 0.01; 0.32) kg/m2, P = 0.03),
and the FUT2 genotype explained 0.05 and 0.02% of the
phenotypic variance in BMI in Inter99 and Health2006,
respectively.
Validation analyses in two German cohorts
Individuals in the German cohorts were middle-aged with
slightly higher BMI than in Inter99 and Health2006 with a
median BMI of 26.8 and 27.5 kg/m2 for SHIP-0 and SHIP-
TREND, respectively (Supplemental Table 5). Serum
vitamin B12 levels were not significantly associated with
BMI (data not shown), but the serum vitamin B12
decreasing FUT2 rs602662 G-allele associated with
increased BMI when combining SHIP-0 and SHIP-TREND
in a fixed-effects meta-analysis [0.27 (95% CI 0.09; 0.44)
kg/m2, P = 0.003]. The FUT2 rs602662 genotype
explained 0.12% of the phenotypic variance of BMI in both
SHIP-0 and SHIP-TREND. When combining the Danish
and the German cohorts, the FUT2 rs602662 showed a
combined per G-allele effect of 0.19 (95% CI 0.08; 0.30)
kg/m2, P = 4 9 10-4 on BMI (Fig. 4). This association
was supported by the European BMI data from the GIANT
consortium where the FUT2 rs602662 G-allele
(n = 233,871) associated nominally with increased BMI
(P = 0.01).
Sensitivity analyses
Results from instrumental variable analysis where each of
the eight SNPs were used as separate instruments (equiv-
alent to a GRS weighted based on the SNP-serum vitamin
B12 association) were similar to results from instrumental
variable analysis based on the simple allele-counting B12
GRS (Supplemental Table 6; Fig. 3). Causal estimates
from MR-Egger regression were largely similar to two-
stage least-squares regression estimates although the esti-
mates from MR-Egger regression were underpowered
(Supplemental Table 5; Supplemental Fig. 1). This was the
case both when including and excluding FUT2 rs602662
and FUT6 rs778805. The intercept from MR-Egger
regression did not differ from zero, neither when excluding
FUT2 rs602662 and FUT6 rs778805, nor when including
these two SNPs (Supplemental Table 6) suggesting that
directional pleiotropy was not present. In support, Funnel
plots were also largely symmetrical (Supplemental Fig. 1).
No interaction was observed between the B12 GRS and
BMI associated SNPs (Supplemental Table 7).
Discussion
We found an observational association between decreased
serum vitamin B12 levels and elevated BMI in two Danish
cohorts. This led to the hypothesis that low serum vitamin
B12 levels are causally involved in body mass regulation,
and we investigated this by applying a Mendelian ran-
domization design, including a formal instrumental vari-
able analysis using a B12 GRS to model an unbiased
genetically induced decrease of serum vitamin B12.
However, our results provided no clear evidence for a
causal role of low serum vitamin B12 levels in obesity.
The Mendelian randomization design applied in this
study may be likened to a randomized clinical trial, where
individuals are randomized by nature to carry genetic
variants associating with low or high circulating levels of
vitamin B12. The purpose of the randomization process in
a clinical trial is to obtain an even distribution of potential
confounders across the treatment arms, and likewise the
Mendelian randomization design should result in an equal
distribution of known and unknown confounders across
genotypes. Additionally, reverse causality (here that higher
BMI causes lower serum vitamin B12 levels) is
Per allele effect of FUT2  rs602662 on BMI (additive model)
Cohort n Weight, % Per allele effect, kg/m2 (95% CI)
Inter99 6.156 44.0 0.16 (0.00;0.32)
Health2006 2910 19.5 0.11 (-0.13;0.35)
SHIP-0 4.064 29.1 0.27 (0.07;0.46 )
SHIP-TREND 986 7.3 0.27 (-0.12;0.66 )
)03.0;80.0(91.0ledomtceffe-dexiF
Heterogeneity, I2 =0.0%, P=0.74
Fig. 4 Association between
FUT2 rs602662 and BMI.
Squares indicate effect
estimates from Inter99 and
Health2006, sized according to
the weight of each study in the
meta-analyses. The diamonds
indicates the effect estimate
from fixed-effects meta-analysis
and error bars indicate 95% CI
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circumvented since genotypes are non-modifiable. Hence,
in the setting of a Mendelian randomization study, geno-
types or a GRS are used as an unconfounded instrument for
the risk factor under investigation and allows a largely
unbiased evaluation of the causal role of the risk factor. To
obtain a proper instrument for serum vitamin B12 levels,
we constructed a GRS consisting of eight vitamin B12
decreasing SNPs in genes encoding proteins from the
pathway responsible for the absorption, processing, and
coenzymatic activity of vitamin B12 [16]. This B12 GRS
associated strongly with serum vitamin B12 and accord-
ingly explained*6% of the phenotypic variance in serum
vitamin B12 levels. For comparison, 97 BMI associated
SNPs from the GIANT consortium cumulatively explain
only 2.7% of the phenotypic variance in BMI [2], which
among many reasons may be due to the unspecific repre-
sentation of numerous different pathways where the vari-
ants are not directly linked functionally. The fact that the
B12 GRS associated strongly and specifically with serum
vitamin B12 levels and the fact that the eight SNPs
included in the B12 GRS all have well-characterized roles
in vitamin B12 functioning, are coding and thus potentially
the true functional SNP, qualifies the B12 GRS as a useful
instrument for evaluating causality. If serum vitamin B12
levels are causally linked to BMI, the B12 GRS should be
related to BMI to the extent predicted by its influence on
serum vitamin B12 levels. Although we did not have suf-
ficient statistical power to completely rule out causality,
our instrumental variable analyses provided no evidence
that low serum vitamin B12 levels cause increased BMI.
A crucial assumption underlying the Mendelian ran-
domization design is that the genotype is associated with
the outcome only via the risk factor under investigation
[17]. However, genetic variants may have pleiotropic
effects and thus influence the outcome through other
pathways than the one under investigation. To circumvent
issues of pleiotropy, we therefore additionally applied the
MR-Egger approach. Inclusion of FUT2 rs602662 and
FUT6 rs778805 as instruments for genetically induced
decreased serum vitamin B12 levels did not support
introduction of directional pleiotropy, but the statistical
power seemed to decrease markedly when applying the
MR-Egger method. Nevetheless, FUT2 rs602662 which
showed the strongest individual SNP effect on serum
vitamin B12, is known to have pleiotropic effects. Thus,
our finding that the G-allele of FUT2 rs602662 was asso-
ciated with decreased levels of serum vitamin B12 as well
as increased BMI, does not necessarily support a causal
role of decreased vitamin B12 levels in obesity. This
finding may be explained by the strong linkage disequi-
librium (r2 = 0.81, D0 = 1.0) between FUT2 rs602662 and
FUT2 rs601338 which encodes a nonsense mutation
(W143X) causing a lack of presentation of blood group
antigens A, B and H on mucosal surfaces and in secretions.
This SNP could potentially modulate the composition and
function of the gut microbiota, a hypothesis that is sup-
ported by various studies. Homozygous carriers of the stop
codon (FUT2 rs601338 AA carriers corresponding to
FUT2 rs602662 AA carriers) are nonsecretors and they
have been shown to be resistant to infections with Heli-
cobacter pylori [27, 28] and Norovirus, the major cause of
viral acute gastroenteritis worldwide [29–32]. Infection
with H. pylori may cause chronic gastritis [33] leading to
decreased secretion of intrinsic factor and therefore
impaired absorption of vitamin B12. Intriguingly, the
resistance to gastrointestinal infections suggests that lack
of blood group antigens on the intestinal mucosa not only
inhibits the infectious potential of pathogenic gastroin-
testinal microbes, but also may inhibit the habitual inter-
action with commensal microbes in the gastrointestinal
tract. This is supported by studies showing that secretor
status influences the composition of the gut microbiota
[34–36]. Also, several studies have reported a link between
gut microbes and human obesity [37–39] and it has been
demonstrated that germ-free mice are leaner than conven-
tionally raised mice and that conventionalization of germ-
free mice with microbiota from conventionally raised mice
results in an increased body fat content [37]. Therefore, the
slightly lower BMI observed among AA carriers of FUT2
rs602662 (accompanied by higher serum vitamin B12
levels) in our study may be explained by the lack of
expression of blood group antigens in the gastrointestinal
tract and therefore impaired cross-talk with commensal
microbes. In support of this interpretation, results from
GIANT showed that the FUT2 rs601338 A-allele (coding
for the stop codon) associated nominally with decreased
BMI (P = 0.007). However, mechanistic studies in rodents
and statistically powered studies of humans involving
characterization of host genotype, microbiota composition,
and BMI, must be conducted to fully address this
hypothesis.
In conclusion, we did not find support for a causal role
of decreased serum vitamin B12 levels in obesity. How-
ever, our study gives rise to the hypothesis that the FUT2
locus explains a part of the observational association
between serum vitamin B12 and BMI through its regula-
tion of the cross-talk between gut microbes and the human
host. Furthermore, the B12 GRS constructed in this study
may be used a valid instrument in future Mendelian ran-
domization studies evaluating of the causal role of serum
vitamin B12 levels in other disorders.
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